Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis
Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.
- Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.
- This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.
- Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life.
- Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT
The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023: